OncBioMune Announces Compelling Pre-Clinical Data for its CD71-Targeted Chemotherapy, PGT, in Models of Lung, Pancreatic and Ovarian Cancers
OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic [...]